186 related articles for article (PubMed ID: 22065089)
1. Evaluation of teicoplanin dosing designs to achieve a new target trough concentration.
Ueda T; Takesue Y; Nakajima K; Ichki K; Wada Y; Tsuchida T; Takahashi Y; Ishihara M; Tatsumi S; Kimura T; Ikeuchi H; Uchino M
J Infect Chemother; 2012 Jun; 18(3):296-302. PubMed ID: 22065089
[TBL] [Abstract][Full Text] [Related]
2. High-dose regimen to achieve novel target trough concentration in teicoplanin.
Ueda T; Takesue Y; Nakajima K; Ichki K; Wada Y; Komatsu M; Tsuchida T; Takahashi Y; Ishihara M; Kimura T; Uchino M; Ikeuchi H
J Infect Chemother; 2014 Jan; 20(1):43-7. PubMed ID: 24462424
[TBL] [Abstract][Full Text] [Related]
3. [Possibility of Poor Outcomes after Treatment Using Teicoplanin at the Minimum Inhibitory Concentration of >2 μg/mL in Methicillin-resistant Staphylococcus aureus Bacteremia].
Kagami K; Imai S; Tazawa Y; Iwasaki S; Fukumoto T; Akizawa K; Yamada T; Ishiguro N; Iseki K
Yakugaku Zasshi; 2018; 138(9):1181-1189. PubMed ID: 30175762
[TBL] [Abstract][Full Text] [Related]
4. Enhanced loading regimen of teicoplanin is necessary to achieve therapeutic pharmacokinetics levels for the improvement of clinical outcomes in patients with renal dysfunction.
Ueda T; Takesue Y; Nakajima K; Ichiki K; Doita A; Wada Y; Tsuchida T; Takahashi Y; Ishihara M; Ikeuchi H; Uchino M; Kimura T
Eur J Clin Microbiol Infect Dis; 2016 Sep; 35(9):1501-9. PubMed ID: 27278654
[TBL] [Abstract][Full Text] [Related]
5. Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: a retrospective study in patients with MRSA infections.
Matsumoto K; Kanazawa N; Ikawa K; Fukamizu T; Shigemi A; Yaji K; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
J Infect Chemother; 2010 Jun; 16(3):193-9. PubMed ID: 20195882
[TBL] [Abstract][Full Text] [Related]
6. Development of a teicoplanin loading regimen that rapidly achieves target serum concentrations in critically ill patients with severe infections.
Nakamura A; Takasu O; Sakai Y; Sakamoto T; Yamashita N; Mori S; Morita T; Nabeta M; Hirayu N; Yoshiyama N; Moroki M; Tashiro K; Kannae M
J Infect Chemother; 2015 Jun; 21(6):449-55. PubMed ID: 25726436
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of factors associated with the achievement of an optimal teicoplanin trough concentration
.
Takechi K; Yanagawa H; Zamami Y; Ishizawa K; Tanaka A; Araki H
Int J Clin Pharmacol Ther; 2017 Aug; 55(8):672-677. PubMed ID: 28655381
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days.
Ueda T; Takesue Y; Nakajima K; Ichiki K; Ishikawa K; Takai Y; Yamada K; Tsuchida T; Otani N; Takahashi Y; Ishihara M; Takubo S; Ikeuchi H; Uchino M; Kimura T
BMC Pharmacol Toxicol; 2020 Jul; 21(1):50. PubMed ID: 32641110
[TBL] [Abstract][Full Text] [Related]
9. Influence of teicoplanin MICs on treatment outcomes among patients with teicoplanin-treated methicillin-resistant Staphylococcus aureus bacteraemia: a hospital-based retrospective study.
Chang HJ; Hsu PC; Yang CC; Siu LK; Kuo AJ; Chia JH; Wu TL; Huang CT; Lee MH
J Antimicrob Chemother; 2012 Mar; 67(3):736-41. PubMed ID: 22169187
[TBL] [Abstract][Full Text] [Related]
10. Significance of individual adjustment of initial loading dosage of teicoplanin based on population pharmacokinetics.
Niwa T; Imanishi Y; Ohmori T; Matsuura K; Murakami N; Itoh Y
Int J Antimicrob Agents; 2010 May; 35(5):507-10. PubMed ID: 20185275
[TBL] [Abstract][Full Text] [Related]
11. Significance of High Trough Concentration of Teicoplanin in the Treatment of Methicillin-Resistant Staphylococcus aureus Infection.
Sato Y; Tokimatsu I; Suzuki Y; Itoh H; Hiramatsu K; Kadota J
Chemotherapy; 2014; 60(4):274-8. PubMed ID: 25926288
[TBL] [Abstract][Full Text] [Related]
12. Development of initial loading procedure for teicoplanin in critically ill patients with severe infections.
Matsumoto K; Kanazawa N; Watanabe E; Yokoyama Y; Fukamizu T; Shimodozono Y; Maeda C; Yasuda T; Kakihana Y; Ikawa K; Morikawa N; Takeda Y
Biol Pharm Bull; 2013; 36(6):1024-6. PubMed ID: 23727923
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic and pharmacodynamic analyses of teicoplanin in Japanese patients with systemic MRSA infection.
Ogawa R; Kobayashi S; Sasaki Y; Makimura M; Echizen H
Int J Clin Pharmacol Ther; 2013 May; 51(5):357-66. PubMed ID: 23458228
[TBL] [Abstract][Full Text] [Related]
14. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.
Hidayat LK; Hsu DI; Quist R; Shriner KA; Wong-Beringer A
Arch Intern Med; 2006 Oct; 166(19):2138-44. PubMed ID: 17060545
[TBL] [Abstract][Full Text] [Related]
15. Exploration of optimal teicoplanin dosage based on pharmacokinetic parameters for the treatment of intensive care unit patients infected with methicillin-resistant Staphylococcus aureus.
Hagihara M; Umemura T; Kimura M; Mori T; Hasegawa T; Mikamo H
J Infect Chemother; 2012 Feb; 18(1):10-6. PubMed ID: 21710160
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of teicoplanin concentrations and safety analysis in neonates.
Yamada T; Kubota T; Nakamura M; Ochiai M; Yonezawa M; Yano T; Kawashiri T; Egashira N; Hara T; Masuda S
Int J Antimicrob Agents; 2014 Nov; 44(5):458-62. PubMed ID: 25218156
[TBL] [Abstract][Full Text] [Related]
17. Weight-based antibiotic dosing in a real-world European study of complicated skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus.
Lawson W; Nathwani D; Eckmann C; Corman S; Stephens J; Solem C; Macahilig C; Li J; Baillon-Plot N; Charbonneau C; Haider S
Clin Microbiol Infect; 2015 Sep; 21 Suppl 2():S40-6. PubMed ID: 26206621
[TBL] [Abstract][Full Text] [Related]
18. Simplified dosing regimens of teicoplanin for patient groups stratified by renal function and weight using Monte Carlo simulation.
Yamada T; Nonaka T; Yano T; Kubota T; Egashira N; Kawashiri T; Oishi R
Int J Antimicrob Agents; 2012 Oct; 40(4):344-8. PubMed ID: 22818770
[TBL] [Abstract][Full Text] [Related]
19. Antibacterial effects of brand-name teicoplanin and generic products against clinical isolates of methicillin-resistant Staphylococcus aureus.
Fujimura S; Fuse K; Takane H; Nakano Y; Gomi K; Kikuchi T; Watanabe A
J Infect Chemother; 2011 Feb; 17(1):30-3. PubMed ID: 20665064
[TBL] [Abstract][Full Text] [Related]
20. Change of teicoplanin loading dose requirement for incremental increases of systemic inflammatory response syndrome score in the setting of sepsis.
Nakano T; Nakamura Y; Takata T; Irie K; Sano K; Imakyure O; Mishima K; Futagami K
Int J Clin Pharm; 2016 Aug; 38(4):908-14. PubMed ID: 27125378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
